SILK - Breaking News: Is Silk Road Medical's $27.50 Per Share Sale Price a Fair Deal? Johnson Fistel LLP Investigates Deal Terms | Benzinga
SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a leading shareholder rights law firm, announced today that it has initiated an investigation into the board members of Silk Road Medical, Inc. (NASDAQ:SILK) concerning potential breaches of fiduciary duties related to the proposed sale of the Company to Boston Scientific (NYSE:BSX).
On June 18, 2024, Silk Road Medical informed the public that it has agreed to a deal with Boston Scientific, in which shareholders will receive $27.50 per share in an all-cash offer.
Johnson Fistel's investigation is centered on determining if the board of directors ...